Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Market On-Q-ity's CTC Platform for Research

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – On-Q-ity today said that Laboratory Corporation of America will market the firm's circulating tumor cell platform to researchers in the biopharma industry.

According to the Waltham, Mass.-based firm, the technology will enable researchers to better stratify patients for potential inclusion or exclusion in clinical trials; more quickly identify patients eligible for study enrollment; better monitor cancer response to treatment; and use CTCs as an earlier indicator of treatment effectiveness.

"On-Q-ity’s CTC platform will provide researchers with a cost-effective, easy-to-use, and extremely accurate test to find and characterize tumor cells circulating in a patient’s blood," On-Q-ity CEO Mara Aspinall said in a statement.

Terms of the alliance were not disclosed.

On-Q-ity is one of several firms developing assays based on circulating tumor cells. Among the others are Advanced Cell Diagnostics and Biocept. Johnson & Johnson company Veridex already markets a circulating tumor cell test called the CellSearch system.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.